08:48 AM EDT, 08/04/2025 (MT Newswires) -- Inmune Bio ( INMB ) shares were up premarket Monday after the company said that a phase I/II trial evaluating Inkmune in men with metastatic castration-resistant prostate cancer met the trial's primary and secondary endpoints.

The therapy was well tolerated across all three dose levels, achieving the trial's safety goal and identifying patients with low NK cell activation as the most responsive group, the company said.

The company said the trial is now closed and that it plans to advance the program by designing a phase 2b trial in patients with less severe disease.